Abstract
The purpose of this study was to evaluate the long-term outcome of interferon (IFN) alfa treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML). Between 1984 and 1990, a total of 71 patients with newly diagnosed CML had been enrolled into two consecutive IFN trials at our institution. Follow-up extended to December 1998, resulting in a median observation period for surviving patients of 11.4 years. The median survival time from diagnosis was 5.9 years. A plateau in the actuarial survival curve was found from 8.2 to 12.3 years following diagnosis with a projected 10-year survival rate of 32%. ‘Landmark’ studies showed a significant survival advantage for patients with karyotype responses. Of 68 patients accessible to calculation of the Hasford score, three were in the high risk group, 24 belonged to the medium risk group, and 41 had low risk features. The majority of cytogenetic responders including all eight assessable patients in complete cytogenetic remission were in the low risk group. Achieving a cytogenetic remission was found to provide a survival advantage also for patients with low risk disease. Of the seven patients surviving more than 11 years, six were in continuous complete cytogenetic remission. Their favorable outcome appears to translate into an out-flattening of the survival curve for the 71 single center patients presented. It will be of interest to see whether prolonged follow-ups of the large multicentric randomized trials will similarly show a subset of long-term surviving patients with ongoing IFN-induced remission.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kantarjian HM, O'Brien S, Anderlini P, Talpaz M . Treatment of chronic myelogenous leukemia: current status and investigational options Blood 1996 87: 3069–3081
Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M . Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy Ann Intern Med 1995 122: 254–261
Chronic Myeloid Leukemia Trialists’ Collaborative Group . Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials J Natl Cancer Inst 1997 89: 1616–1620
Hasford J, Pfirrmann M, Hehlmann R, Allen NC, Baccarani M, Kluin-Nelemanns JC, Alimena G, Steegmann JL, Ansari H . A new prognostic score for patients with chronic myeloid leukemia treated with interferon alfa J Natl Cancer Inst 1998 90: 850–858
Kloke O, Niederle N, Qiu JY, Wandl U, Moritz T, Nagel-Hiemke M, Opalka B, Seeber S, Becher R . Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia Br J Haematol 1993 83: 399–403
Kloke O, Wandl U, Opalka B, Moritz T, Nagel-Hiemke M, Franz T, Hirche H, Seeber S, Niederle N . A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia Eur J Haematol 1992 48: 93–98
Niederle N, Kloke O, Wandl UB, Becher R, Moritz T, Opalka B . Long-term treatment chronic myelogenous leukemia with different interferons: results from three studies Leuk Lymphoma 1993 9: 111–119
Talpaz M, Kantarjian HM, McCredie KB, Trujillo K, Keating MJ, Gutterman JU . Clinical investigation of human alpha interferon in chronic myelogenous leukemia Blood 1987 72: 1280–1288
Kaplan EM, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 1959 22: 719–748
The Italian Cooperative Study Group on Chronic Myeloid Leukemia . Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia Blood 1998 92: 1541–1548
Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falga C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, von Wussow P, Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H, and the German CML study group . Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia Blood 1994 84: 4064–4077
Acknowledgements
We are grateful to R Prittwitz and I Hawig for assistance in the collection and management of clinical data.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kloke, O., Opalka, B. & Niederle, N. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center. Leukemia 14, 389–392 (2000). https://doi.org/10.1038/sj.leu.2401661
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401661
Keywords
This article is cited by
-
Allogeneic bone marrow transplantation in the developing world: experience from a center in India
Bone Marrow Transplantation (2001)